35 completed, 10 terminated, 9 unknown, 5 recruiting. 26 Phase 2, 25 Phase 3, 9 Phase 4, 4 Phase 1, 2 Not applicable.
Follow lanreotide: new trials by email Literature Review of lanreotide trials Research Report on lanreotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., Amino acid solution - Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) | Phase 3 | Recruiting | Grupo Espanol de Tumores Neuroendocrinos | 166 | 2025-06-12 | 2026-09-16 |
| Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula Biospecimen Collection, Distal Pancreatectomy, Lanreotide - Pancreatic Carcinoma, Pancreatic Neoplasm | Phase 3 | Recruiting | SWOG Cancer Research Network | 274 | 2025-05-09 | 2026-03-31 |
| Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients Somatostatin analog - Gastroenteropancreatic Neuroendocrine Tumor | Phase 4 | Recruiting | University Hospital, Antwerp | 270 | 2023-06-28 | 2024-06-14 |
| A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Debio 4126, Sandostatin LAR, Somatuline ATG - Acromegaly, GEP-NET | Phase 1 | Terminated | Debiopharm International SA | 19 | 2022-05-18 | 2025-11-17 |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy RYZ101, Everolimus, Sunitinib - GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor | Phase 3 | Active not recruiting | RayzeBio, Inc. | 343 | 2022-03-24 | 2026-10-05 |
| Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors Cabozantinib, Lanreotide - Neuroendocrine Tumors,Gastroenteropancreatic | Phase 1 / Phase 2 | Recruiting | National Health Research Institutes, Taiwan | 49 | 2021-09-17 | 2026-04-09 |
| A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET Cabozantinib, Lanreotide - Metastatic Well Differentiated Neuroendocrine Neoplasm, Neuroendocrine Tumors | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 69 | 2020-06-20 | 2021-09-05 |
| Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome Telotristat Ethyl, Lanreotide - Small Intestinal NET, Carcinoid Heart Disease | Phase 3 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2020-04-01 | 2020-02-05 | |
| Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands IONIS GHR-LRx, Somatostatin Receptor Ligand (SRL) - Acromegaly | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 39 | 2019-07-25 | 2023-03-22 |
| LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) Lanreotide - Paraganglioma, Pheochromocytoma | Phase 2 | Active not recruiting | Antonio Fojo | 10 | 2019-06-17 | 2026-03-02 |
| Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Gamma knife radiosurgery, Lanreotide 60Mg Solution for Injection - Acromegaly Due to Pituitary Adenoma | Phase 3 | Unknown | Samsung Medical Center | 90 | 2018-03-01 | 2018-03-01 |
| A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula Lanreotide Prefilled Syringe - Pancreatic Leak, Pancreatic Fistula | Phase 2 | Completed | University of Washington | 114 | 2018-02-20 | 2022-06-16 |
| The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research Transnasal butterfly surgery, sandostatin, radiotherapy - Acromegaly | Recruiting | Ginkgo Leaf Center for Rare Disorders | 1965 | 2017-12-15 | 2022-03-16 | |
| Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres Lanreotide, Y-90 microspheres - Neuroendocrine Tumors, Gastrointestinal Neoplasms | Phase 2 | Terminated | SCRI Development Innovations, LLC | 6 | 2017-07-28 | 2023-12-05 |
| Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Lanreotide - Neuroendocrine Tumors | Phase 4 | Unknown | Samsung Medical Center | 28 | 2017-07-05 | 2019-05-20 |
| Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors Lanreotide, Pembrolizumab - Gastroenteropancreatic Neuroendocrine Tumors | Phase 1 / Phase 2 | Completed | Duke University | 22 | 2017-07-01 | 2023-06-29 |
| Lanreotide in the Treatment of Small Bowel Motility Disorders Lanreotide - Gastrointestinal Motility Disorder, Intestinal Disease | Phase 2 | Completed | Northwell Health | 12 | 2017-05-11 | 2021-01-15 |
| Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours Lanreotide (Autogel formulation), Placebo, Best Supportive Care - Neuroendocrine Tumors in Lung | Phase 3 | Terminated | Ipsen | 77 | 2017-03-06 | 2022-07-06 |
| Circulating Tumor Cells and Tumor DNA in HCC and NET Sorafenib, Radiofrequency ablation (RFA) or surgery, Everolimus - Carcinoma, Hepatocellular, Neuroendocrine Tumors | Completed | University of Aarhus | 167 | 2016-11-01 | 2021-04-28 | |
| Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. Lanreotide (Autogel formulation) and Temozolomide - Neuroendocrine Tumours | Phase 2 | Completed | Ipsen | 40 | 2016-07-01 | 2020-10-01 |
Showing 20 of 63. Sign in to see all of them.
Acromegaly (21) · Neuroendocrine Tumors (14) · Carcinoid Tumor (5) · Gastro-enteropancreatic neuroendocrine tumor (4) · Polycystic liver disease (4) · Polycystic Kidney, Autosomal Dominant (3) · Carcinoma, Hepatocellular (2) · Diarrhea (2) · Dumping Syndrome (2) · Hepatomegaly (2) · Intestinal Obstruction (2) · Liver Diseases (2) · Neoplasm Metastasis (2) · Pituitary Neoplasms (2) · Polycystic Kidney Diseases (2)
Ipsen (25) · Radboud University Medical Center (4) · Federico II University (3) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · Samsung Medical Center (2) · University of Aarhus (2) · Antonio Fojo (1) · Assistance Publique - Hôpitaux de Paris (1) · Cedars-Sinai Medical Center (1) · Dana-Farber Cancer Institute (1) · Debiopharm International SA (1) · Duke University (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Federation Francophone de Cancerologie Digestive (1) · GERCOR - Multidisciplinary Oncology Cooperative Group (1)
United States (17) · France (15) · Italy (15) · Belgium (14) · Netherlands (13) · Spain (10) · United Kingdom (10) · Germany (8) · Denmark (7) · Poland (7) · Czechia (6) · Russia (3) · South Korea (3) · Sweden (3) · Australia (2)
Annamaria Colao, MD, PhD (2) · Frederik Nevens, MD, PhD (2) · Joost PH Drenth, MD, PhD (2) · Loes van Keimpema, MSc (2) · Sara Pusceddu, MD (2) · Angela Lamarca (1) · Annamaria Colao, MD (1) · Antonio Fojo, MD, PhD (1) · Come Lepage, Pr (1)
PMID 39356039, PMID 17259801, PMID 25014687, PMID 33052555, PMID 10207464, PMID 10517918, PMID 10573522, PMID 10792333, PMID 10811995, PMID 10984283, PMID 11788630, PMID 12066229, PMID 12198662, PMID 12540801, PMID 12591191, PMID 12759473, PMID 12902325, PMID 14762851, PMID 14769829, PMID 14974910, PMID 15080776, PMID 15080778, PMID 15099442, PMID 15246216, PMID 15362960, PMID 15588232, PMID 15613435, PMID 15649100, PMID 15827109, PMID 16801334, PMID 16918950, PMID 16953241, PMID 17555511, PMID 17589893, PMID 17892497, PMID 17984237, PMID 18248639, PMID 18445662, PMID 18810319, PMID 19001517, PMID 19094074, PMID 19542735, PMID 19639415, PMID 19898989, PMID 21086246, PMID 21148630, PMID 21252315, PMID 21306237, PMID 22475206, PMID 23109694
2004 (3), 2014 (3), 2005 (2), 2008 (2), 2019 (2), 2009 (1), 2015 (1), UG1CA189974 (1)